Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de bioequivalencia de dos tabletas de roxitromicina en sujetos sanos

12 de noviembre de 2026 actualizado por: Yan He, The Affiliated Hospital Of Guizhou Medical University

Un estudio de bioequivalencia cruzada de dosis, en ayunas, a aleatorios, de dos tratamientos, de tres tratamiento, parcialmente replicados, con corrección de bioequivalencia de referencia de tabletas de roxitromicina en sujetos sanos

Roxithromycin is used for the treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media, acute bronchitis, acute exacerbations of chronic bronchitis, and pneumonia caused by Mycoplasma pneumoniae or Chlamydia pneumoniae; urethritis and cervicitis caused by Chlamydia trachomatis; and skin and soft tissue infections caused by susceptible bacteria.

The purpose of this study was to evaluate the bioequivalence of roxithromycin tablets from two different manufacturers after fasting administration in healthy subjects and to observe the safety of the test and reference preparations in healthy subjects.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

39

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Guiyang, Porcelana
        • Clinical Trials Center, The Affiliated Hospital of Guizhou Medical University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Chinese healthy adults over 18 years old ( including 18 years old ) ;
  • Weight : male ≥ 50.0kg, female ≥ 45.0kg and body mass index ( BMI ) :

19.0 ~ 26.0kg / m2 ( including boundary value, BMI = weight ( kg ) / height ( m ) 2 ) ;

  • Understand and sign the informed consent, volunteer to participate in this study ;
  • Be able to communicate well with the researchers and complete the study in accordance with the provisions of the study.

Exclusion Criteria:

  • There is a history of diseases such as cardiovascular system, respiratory system, digestive system, endocrine system, nervous / mental system, blood and lymphatic system, skeletal muscle system, family genetic disease history and so on;

  • Patients who had undergone major surgery within 1 year before screening and were judged not suitable for enrollment by the researchers;

  • Comprehensive physical examination, vital signs, 12-lead electrocardiogram, laboratory tests [ including blood routine, urine routine, blood biochemistry, coagulation function, blood pregnancy ( only female subjects ) ], etc., suggested that there were abnormalities judged by the researchers as clinically significant ;

  • electrolyte potassium < 3.5mmol / L or magnesium < 0.75mmol / L in blood biochemistry ;

  • hepatitis B surface antigen ( HBsAg ), hepatitis B e antigen ( HBeAg ), hepatitis C antibody ( HCV-Ab ), human immunodeficiency virus antibody ( HIV-Ab ), treponema pallidum antibody ( TP-Ab ) any test results positive ;

  • the existence of researchers judged to have clinical significance of food, drug allergy or other allergic disease history ( asthma, urticaria, eczematous dermatitis, etc. ) or the product and its excipients or its analogues allergy ;

  • Patients who used any drugs that interact with roxithromycin within 30 days before screening ( such as contraceptives, ergotamine/dihydroergotamine, theophylline, anticoagulants, digoxin and other cardiac glycosides, midazolam, cyclosporine, drugs that can prolong QT interval [antidepressants ( such as citalopram ), antiarrhythmic drugs ( such as sotalol, amiodarone ), cisapride, antipsychotics ( such as clozapine

    • antibiotics ( such as erythromycin ) ] ;
  • who had used any drug within 2 weeks before screening, and was judged by the researcher to be likely to affect the evaluation results of this study ;

  • Patients with a history of drug abuse / drug dependence or positive urine screening within 12 months before screening ;

  • Patients who drank more than 14g alcohol per week ( 1 unit = 360ml beer or 45ml alcohol with 40 % alcohol or 150ml wine ) within 6 months before screening, or who could not give up drinking during the trial, or who were positive for alcohol breath test ;

  • patients who had long-term excessive drinking ( more than 8 cups a day, 1 cup = 250ml ) of tea, coffee or caffeine-containing beverages ;

  • Smoking ≥ 3 cigarettes per day within 3 months before screening or those who could not guarantee to give up smoking during the trial ;

  • Patients who participated in other drug clinical trials and took research drugs within 3 months before screening ( the last visit time of the last trial was calculated as the start time ) ;

  • Screening for blood donation or blood products or massive bleeding > 200ml or 1 unit within the first 3 months, or planning to donate blood or blood components during the study period ;

  • Do not agree to avoid the use of tobacco ( including any nicotine-containing smoking cessation products such as nicotine lozenges, nicotine gum ), wine or xanthine, grapefruit, caffeine ( such as coffee, strong tea, chocolate, etc. ) drinks or food ( such as animal liver, mango, pitaya, etc. ), or to avoid strenuous exercise, or to avoid other factors affecting drug absorption, distribution, metabolism, excretion, etc. ;

  • Pregnant or lactating women, or those with positive pregnancy test results before the test ; male subjects or female subjects were unwilling to take one or more non-drug contraceptive measures ( such as complete abstinence, contraceptive ring, partner ligation, etc. ) during the trial, or had sperm / egg donation plans or male subjects ( or their partners ), female subjects had fertility plans ( from the signing of informed consent to 3 months after the last administration ) ;

  • patients with difficulty in venous blood collection or fainting ;

  • tablet swallowing difficulties ;

  • those who have special requirements for diet, cannot abide by the diet provided and the corresponding regulations ;

  • Subjects who were considered inappropriate to participate in this clinical study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Un grupo T-R-R

Oral roxithromycin tablets,150mg Once every seven days,One cycle T drug, two cycles R drug

Experimental: B Grupo R-T-R

Oral roxithromycin tablets,150mg Once every seven days,One cycle T drug, two cycles R drug

Experimental: C Group R-R-T

Oral roxithromycin tablets,150mg Once every seven days,One cycle T drug, two cycles R drug

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
maximum observed serum or plasma concentration
Periodo de tiempo: 3 day

The with-subject standard deviation of the pharmacokinetic parameter Cmax of the reference preparation was calculated and the bioequivalence was analyzed according to the bioequivalence evaluation criteria.

3 day
area under the serum or plasma concentration-time curve from 0 to t
Periodo de tiempo: 3 day

The with-subject standard deviation of the pharmacokinetic parameter AUC0-t of the reference preparation was calculated and the bioequivalence was analyzed according to the bioequivalence evaluation criteria.

3 day
area under the serum or plasma concentration-time curve from 0 to infinity
Periodo de tiempo: 3 day

The with-subject standard deviation of the pharmacokinetic parameter AUC0- ∞ of the reference preparation was calculated and the bioequivalence was analyzed according to the bioequivalence evaluation criteria.

3 day

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de junio de 2019

Finalización primaria (Actual)

6 de agosto de 2019

Finalización del estudio (Actual)

3 de septiembre de 2019

Fechas de registro del estudio

Enviado por primera vez

14 de enero de 2025

Primero enviado que cumplió con los criterios de control de calidad

22 de enero de 2025

Publicado por primera vez (Actual)

29 de enero de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de enero de 2025

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • KL288-1-BE-01

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir